WO2000036089A3 - Methods of immunosuppression - Google Patents

Methods of immunosuppression Download PDF

Info

Publication number
WO2000036089A3
WO2000036089A3 PCT/GB1999/004233 GB9904233W WO0036089A3 WO 2000036089 A3 WO2000036089 A3 WO 2000036089A3 GB 9904233 W GB9904233 W GB 9904233W WO 0036089 A3 WO0036089 A3 WO 0036089A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
antigen
immunosuppression
methods
allergen
Prior art date
Application number
PCT/GB1999/004233
Other languages
French (fr)
Other versions
WO2000036089A2 (en
Inventor
Jonathan Robert Lamb
Margaret Jane Dallman
Gerard Francis Hoyne
Original Assignee
Lorantis Ltd
Jonathan Robert Lamb
Margaret Jane Dallman
Gerard Francis Hoyne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lorantis Ltd, Jonathan Robert Lamb, Margaret Jane Dallman, Gerard Francis Hoyne filed Critical Lorantis Ltd
Priority to JP2000588338A priority Critical patent/JP2002532086A/en
Priority to NZ512412A priority patent/NZ512412A/en
Priority to AU17895/00A priority patent/AU768236B2/en
Priority to CA002354147A priority patent/CA2354147A1/en
Priority to EP99961206A priority patent/EP1141243A2/en
Publication of WO2000036089A2 publication Critical patent/WO2000036089A2/en
Publication of WO2000036089A3 publication Critical patent/WO2000036089A3/en
Priority to US09/870,902 priority patent/US20010048930A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Abstract

A method for producing a T cell having tolerance to an allergen or antigen which method comprises incubating the T cell with an antigen presenting cell (APC) in the presence of (i) a composition capable of upregulating expression of an endogenous Notch ligand in the APC and (ii) the allergen or antigen is provided.
PCT/GB1999/004233 1998-12-15 1999-12-15 Methods of immunosuppression WO2000036089A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000588338A JP2002532086A (en) 1998-12-15 1999-12-15 Immunosuppression method
NZ512412A NZ512412A (en) 1998-12-15 1999-12-15 Methods of immunosuppression
AU17895/00A AU768236B2 (en) 1998-12-15 1999-12-15 Methods of immunosuppression
CA002354147A CA2354147A1 (en) 1998-12-15 1999-12-15 Methods of immunosuppression
EP99961206A EP1141243A2 (en) 1998-12-15 1999-12-15 Methods of immunosuppression
US09/870,902 US20010048930A1 (en) 1999-12-15 2001-05-31 Methods of immunosuppression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9827604.1 1998-12-15
GBGB9827604.1A GB9827604D0 (en) 1998-12-15 1998-12-15 Methods of immunosuppression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/870,902 Continuation US20010048930A1 (en) 1999-12-15 2001-05-31 Methods of immunosuppression

Publications (2)

Publication Number Publication Date
WO2000036089A2 WO2000036089A2 (en) 2000-06-22
WO2000036089A3 true WO2000036089A3 (en) 2000-10-26

Family

ID=10844262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/004233 WO2000036089A2 (en) 1998-12-15 1999-12-15 Methods of immunosuppression

Country Status (7)

Country Link
EP (1) EP1141243A2 (en)
JP (1) JP2002532086A (en)
AU (1) AU768236B2 (en)
CA (1) CA2354147A1 (en)
GB (1) GB9827604D0 (en)
NZ (1) NZ512412A (en)
WO (1) WO2000036089A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB0019242D0 (en) * 2000-08-04 2000-09-27 Lorantis Ltd Assay
GB0118155D0 (en) * 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
WO2003011317A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
GB0220658D0 (en) * 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
WO2004032969A1 (en) * 2002-10-09 2004-04-22 Lorantis Limited Modulation of immune function
GB0300428D0 (en) * 2003-01-09 2003-02-05 Lorantis Ltd Medical treatment
WO2004064863A1 (en) * 2003-01-23 2004-08-05 Lorantis Limited Treatment of autoimmune diseases using an activator for the notch signaling pathway
ATE474593T1 (en) * 2003-03-21 2010-08-15 Celldex Therapeutics Ltd TREATMENT OF ALLERGIC DISEASES USING A MODULATOR OF THE NOTCH SIGNALING PATHWAY
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006657A1 (en) * 1993-08-30 1995-03-09 The General Hospital Corporation Interleukin-10 and immunosuppression
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1998020142A1 (en) * 1996-11-07 1998-05-14 Lorantis Limited Notch

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006657A1 (en) * 1993-08-30 1995-03-09 The General Hospital Corporation Interleukin-10 and immunosuppression
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1998020142A1 (en) * 1996-11-07 1998-05-14 Lorantis Limited Notch

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOYNE GERARD F ET AL: "Linked suppression in peripheral T cell tolerance to the house dust mite derived allergen Der p 1.", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 118, no. 2-4, February 1999 (1999-02-01), pages 122 - 124, XP000929560 *
HOYNE GERARD F ET AL: "Serrate 1-induced Notch signalling regulates the decision between immunity and tolerance made by peripheral CD4+ T cells.", INTERNATIONAL IMMUNOLOGY., vol. 12, no. 2, February 2000 (2000-02-01), pages 177 - 185, XP000929552 *

Also Published As

Publication number Publication date
WO2000036089A2 (en) 2000-06-22
AU1789500A (en) 2000-07-03
NZ512412A (en) 2004-04-30
JP2002532086A (en) 2002-10-02
GB9827604D0 (en) 1999-02-10
AU768236B2 (en) 2003-12-04
EP1141243A2 (en) 2001-10-10
CA2354147A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
WO2000036089A3 (en) Methods of immunosuppression
WO2000001845A3 (en) Method for early diagnosis of carcinomas
EP0945602A3 (en) Direct-injection diesel engine and combustion method for the same
AU3171399A (en) Solid electrolyte fuel cell and method of producing the same
AU2001292539A1 (en) Fuel cell assembly and method for making the same
AU2866197A (en) Diagnostic test carrier with multi-layer test field and method in which it is used to determine an analyte
CA2218751A1 (en) A silicon substrate having a recess for receiving an element, and a method of producing such a recess
AU9231998A (en) Antigen presenting mesenchymal stem cells
AU4926897A (en) Method of producing semiconductor member and method of producing solar cell
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
AU2003279229A1 (en) Fuel cell assembly and method of making the same
AU6505299A (en) Methods for generating antigen-reactive t cells (in vitro)
AU1152397A (en) Methods for in vivo t cell activation by antigen-pulsed dendritic cells
AU4086099A (en) Fuel injector
WO1998026286A3 (en) Sandwich assays for collagen type i fragments
EP0913574A3 (en) Fuel injector solenoid utilizing an apertured armature
AU6386599A (en) Servo-controlled fuel injector with leakage limiting device
MX9708697A (en) Method of diagnosing prostate cancer.
AR017216A1 (en) METHOD FOR REGULATING PHAGOCITOSIS OF CELLS OF MAMMALS.
WO2002077627A3 (en) Patch-clamping and its use in analysing subcellular features
WO1999043703A8 (en) Method for immunochemically assaying anti-hm1.24 antibody
WO2000033880A3 (en) Conjugate used for enriching in neuronal cells
AU2284997A (en) Marker for male infertility and/or fertility
IL133881A0 (en) Decreased fat adsorption with an anti-lipase antibody
EP0315058A3 (en) Method for self-performing enzyme kinetics

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17895

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999961206

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 17895/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09870902

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2354147

Country of ref document: CA

Ref country code: CA

Ref document number: 2354147

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 588338

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 512412

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1999961206

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 17895/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999961206

Country of ref document: EP